Wall Street analysts forecast that Sierra Oncology (NASDAQ:SRRA) will report earnings per share of ($0.17) for the current quarter, according to Zacks. Zero analysts have made estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.17). Sierra Oncology reported earnings per share of ($0.20) in the same quarter last year, which suggests a positive year over year growth rate of 15%. The company is expected to announce its next earnings report on Thursday, August 9th.
According to Zacks, analysts expect that Sierra Oncology will report full-year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.68). For the next fiscal year, analysts expect that the firm will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.78) to ($0.72). Zacks’ EPS averages are an average based on a survey of analysts that cover Sierra Oncology.
Get Sierra Oncology alerts:Sierra Oncology (NASDAQ:SRRA) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02.
SRRA has been the topic of several analyst reports. Zacks Investment Research lowered Sierra Oncology from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. ValuEngine upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd.
Shares of NASDAQ SRRA traded down $0.05 during trading on Monday, hitting $2.57. 453,200 shares of the company were exchanged, compared to its average volume of 563,468. Sierra Oncology has a 12-month low of $1.10 and a 12-month high of $4.09. The firm has a market cap of $194.70 million, a PE ratio of -3.06 and a beta of 2.37.
A number of institutional investors and hedge funds have recently modified their holdings of SRRA. Acadian Asset Management LLC raised its holdings in Sierra Oncology by 112.3% in the 4th quarter. Acadian Asset Management LLC now owns 32,437 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 17,161 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in Sierra Oncology in the 4th quarter valued at about $2,238,000. Bank of New York Mellon Corp purchased a new stake in Sierra Oncology in the 4th quarter valued at about $280,000. Sphera Funds Management LTD. purchased a new stake in Sierra Oncology in the 4th quarter valued at about $2,052,000. Finally, AWH Capital L.P. purchased a new stake in Sierra Oncology in the 4th quarter valued at about $2,555,000. Hedge funds and other institutional investors own 66.67% of the company’s stock.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Get a free copy of the Zacks research report on Sierra Oncology (SRRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment